Ge Fujing相关文献与解析，生知库 | 链接生命科学的每一步

Josephin Domain Containing 2 (JOSD2) inhibition as Pan-KRAS-mutation-targeting strategy for colorectal cancer.

Josephin结构域包含2 (JOSD2) 抑制作为泛KRAS突变靶向策略治疗结直肠癌

Yuan Tao, Liu Yue, Wu Ruilin, Qian Meijia, Wang Weihua, Li Yonghao, Zhu Hongdao, Wang Jia'er, Ge Fujing, Zeng Chenming, Dai Xiaoyang, Hu Ronggui, Zhou Tianhua, He Qiaojun, Zhu Hong, Yang Bo

肿瘤

UniMap: Type-Level Integration Enhances Biological Preservation and Interpretability in Single-Cell Annotation

UniMap：类型级整合增强单细胞注释中的生物学保存性和可解释性

期刊:Advanced Science

影响因子:14.1

doi:10.1002/advs.202410790

Hu, Haitao; Guo, Yue; Ge, Fujing; Yin, Hao; Zhang, Hao; Zhou, Zhesheng; Yan, Fangjie; Ye, Qing; Wu, Jialu; Cao, Ji; Hsieh, Chang-Yu; Yang, Bo

Deubiquitinating enzyme JOSD2 affects susceptibility of non-small cell lung carcinoma cells to anti-cancer drugs through DNA damage repair

去泛素化酶JOSD2通过DNA损伤修复影响非小细胞肺癌细胞对抗癌药物的敏感性。

期刊:Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences

影响因子:

doi:10.3724/zdxbyxb-2023-0256

Ge, Fujing; Liu, Xiangning; Zhang, Hongyu; Yuan, Tao; Zhu, Hong; Yang, Bo; He, Qiaojun

The effect of PLK1 inhibitor in osimertinib resistant non-small cell lung carcinoma cells.

PLK1抑制剂对奥希替尼耐药的非小细胞肺癌细胞的影响

期刊:Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences

影响因子:

doi:10.3724/zdxbyxb-2023-0305

Dai Xiaoyang, Liu Xiangning, Ge Fujing, Zhu Hongdao, Zheng Churun, Yan Fangjie, Yang Bo

Nanovaccines for lung cancer: Platforms, mechanistic insights, and translational challenges

肺癌纳米疫苗：平台、机制解析及转化挑战

Josephin Domain Containing 2 (JOSD2) inhibition as Pan-KRAS-mutation-targeting strategy for colorectal cancer.

Josephin结构域包含2 (JOSD2) 抑制作为泛KRAS突变靶向策略治疗结直肠癌

UniMap: Type-Level Integration Enhances Biological Preservation and Interpretability in Single-Cell Annotation

UniMap：类型级整合增强单细胞注释中的生物学保存性和可解释性

Deubiquitinating enzyme JOSD2 affects susceptibility of non-small cell lung carcinoma cells to anti-cancer drugs through DNA damage repair

去泛素化酶JOSD2通过DNA损伤修复影响非小细胞肺癌细胞对抗癌药物的敏感性。

The effect of PLK1 inhibitor in osimertinib resistant non-small cell lung carcinoma cells.

PLK1抑制剂对奥希替尼耐药的非小细胞肺癌细胞的影响